{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06066645",
            "orgStudyIdInfo": {
                "id": "GLK-101-01"
            },
            "organization": {
                "fullName": "Glaukos Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone",
            "officialTitle": "Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose\u00ae TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hypertension",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "travoprost-intraocular-implant-istent-infinite-vs-istent-infinite-alone"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-27",
            "studyFirstSubmitQcDate": "2023-09-27",
            "studyFirstPostDateStruct": {
                "date": "2023-10-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-27",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Glaukos Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Glaucoma, Open-Angle"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "iDose TR",
                    "type": "EXPERIMENTAL",
                    "description": "Travoprost Intraocular Implant in subjects who had successful iStent infinite placement",
                    "interventionNames": [
                        "Drug: Travoprost Intraocular Implant",
                        "Device: iStent infinite"
                    ]
                },
                {
                    "label": "sham procedure",
                    "type": "SHAM_COMPARATOR",
                    "description": "Sham surgical procedure in subjects who had successful iStent infinite placement",
                    "interventionNames": [
                        "Other: Sham procedure",
                        "Device: iStent infinite"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Travoprost Intraocular Implant",
                    "description": "anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite",
                    "armGroupLabels": [
                        "iDose TR"
                    ],
                    "otherNames": [
                        "iDose TR"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Sham procedure",
                    "description": "Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite",
                    "armGroupLabels": [
                        "sham procedure"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "iStent infinite",
                    "description": "Successful iStent infinite surgery",
                    "armGroupLabels": [
                        "iDose TR",
                        "sham procedure"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "change from baseline in mean diurnal intraocular pressure (IOP)",
                    "description": "mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline",
                    "timeFrame": "3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* diagnosis of open-angle glaucoma or ocular hypertension\n* qualifying IOP in the study eye\n\nExclusion Criteria:\n\n* unmedicated (washed out) IOP of \\>36 mmHg in the study eye\n* hypersensitivity to travoprost or any other components of the travoprost intraocular implant\n* vertical cup/disc ratio \\> 0.8 in the study eye\n* best spectacle corrected visual acuity of worse than 20/80 in either eye eye\n* any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director",
                    "role": "CONTACT",
                    "phone": "949-481-8076",
                    "email": "idose@glaukos.com"
                },
                {
                    "name": "Study Manager",
                    "role": "CONTACT",
                    "phone": "949-481-8076",
                    "email": "idose@glaukos.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "Glaukos Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Glaukos Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Colorado Springs",
                    "state": "Colorado",
                    "zip": "80907",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Director",
                            "role": "CONTACT",
                            "phone": "949-481-8076",
                            "email": "idose@Glaukos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.83388,
                        "lon": -104.82136
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005901",
                    "term": "Glaucoma"
                },
                {
                    "id": "D000005902",
                    "term": "Glaucoma, Open-Angle"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009798",
                    "term": "Ocular Hypertension"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M9013",
                    "name": "Glaucoma",
                    "asFound": "Glaucoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9014",
                    "name": "Glaucoma, Open-Angle",
                    "asFound": "Glaucoma, Open-Angle",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12731",
                    "name": "Ocular Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069557",
                    "term": "Travoprost"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M466",
                    "name": "Travoprost",
                    "asFound": "G/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}